Innate Pharma (IPHYF)
Innate Pharma S.A. is a France-based biotechnology company focused on developing immunotherapies for cancer patients in France and other international markets. The company’s pipeline includes several clinical-stage candidates, such as Lacutamab (IPH4102) for cutaneous T-cell and peripheral T-cell lymphoma and refractory Sézary syndrome, Monalizumab for advanced solid tumors including colorectal, lung, and head and neck cancers, and IPH5201, which targets the CD39 immunosuppressive pathway. Additional programs include IPH5301, IPH6401, IPH6101, and IPH62, along with preclinical assets such as IPH43, IPH45, and IPH67. Innate Pharma also maintains licensing, collaboration, and co-development arrangements with AstraZeneca, Novo Nordisk A/S, Sanofi, Orega Biotech, and MedImmune Limited. The company was incorporated in 1999 and is based in Marseille, France. Its common stock is listed on OTC Markets.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-IPHY.F
|
$1.60
|
-2.8% Downside
|
Fair
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
September 17, 2026
|
-2.9x
|
-6.6x
|
15.8x
|
161 M
|
141.3 M
|
14.0%
|
75.2%
|
-24.4
|
—
|
107.6%
|
